CAS Institute of Biophysics
CAS Institute of Biophysics
CAS Institute of Biophysics | Date: 2017-08-30
Disclosed In the present application is micellar polypeptide vaccine having PEGylated phospholipid as carrier. The vaccine can prevent or treat tumors or can be used as combination formulation with anti-cancer activity formulation. The micellar polypeptide vaccine Is formed of self-assembling PEGylated phospholipid (PEG-PE) and antigenic polypeptides, the PEGylated phospholipid being compound formed of polyethylene glycol (hydrophilic blocks) covalently bonded to nitrogenous bases on phospholipid molecule (hydrophobic blocks). The particle diameter of the micellar vaccine is 10-100nm, and the antigenic polypeptides carried therein are polypeptides of 5-100 amino acid. The Micellar polypeptide vaccine may also contain immunoadjuvant.
CAS Institute of Biophysics | Date: 2017-04-05
The present disclosure relates to a tumor-targeted drug delivery system, comprising a tumor-targeted drug carrier and a tumor-treating drug, wherein the tumor-targeted drug carrier comprises full heavy-chain human ferritin. The present disclosure also relates to a method for preparing the tumor-targeted drug delivery system comprising: depolymerizing a polymerized full heavy-chain human ferritin; adding a tumor-treating drug to the depolymerized full heavy-chain human ferritin so as to bind the tumor-treating drug to the depolymerized full heavy-chain human ferritin; and re-polymerizing the depolymerized full heavy-chain human ferritin bound with the tumor-treating drug to form a nanoparticle.
CAS Institute of Biophysics | Date: 2017-06-28
The present invention provides methods and compositions for treating and/or preventing a disease or disorder associated with abnormally high level of the IFP35 family of proteins, including IFP35 and NMI, methods and compositions for diagnosis, prognosis or treatment monitoring of a disease or disorder associated with abnormally high level of the IFP35 family of proteins, including IFP35 and NMI, and methods and compositions for identifying a modulator of the IFP35 family of proteins, including IFP35 and NMI.
Luo Y.,CAS Institute of Biophysics
Cell Research | Year: 2017
The persistence of cholesterol-engorged macrophages (foam cells) in the artery wall fuels the development of atherosclerosis. However, the mechanism that regulates the formation of macrophage foam cells and impedes their emigration out of inflamed plaques is still elusive. Here, we report that adhesion receptor CD146 controls the formation of macrophage foam cells and their retention within the plaque during atherosclerosis exacerbation. CD146 is expressed on the macrophages in human and mouse atheroma and can be upregulated by oxidized low-density lipoprotein (oxLDL). CD146 triggers macrophage activation by driving the internalization of scavenger receptor CD36 during lipid uptake. In response to oxLDL, macrophages show reduced migratory capacity toward chemokines CCL19 and CCL21; this capacity can be restored by blocking CD146. Genetic deletion of macrophagic CD146 or targeting of CD146 with an antibody result in much less complex plaques in high-fat diet-fed ApoE-/- mice by causing lipid-loaded macrophages to leave plaques. Collectively, our findings identify CD146 as a novel retention signal that traps macrophages within the artery wall, and a promising therapeutic target in atherosclerosis treatment.Cell Research advance online publication 13 January 2017; doi:10.1038/cr.2017.8. © 2017 Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences
CAS Institute of Biophysics and Gill Biotechnology Tianjin Co. | Date: 2016-11-23
This invention provides a nanozyme immunochromatographic detection method for detecting a substance to be tested in a liquid sample, comprising, in this order, the steps of:1) providing a detection probe, which is prepared by coupling a magnetic nanoparticle to a first molecule capable of specifically binding to the substance to be tested;2) providing a capture probe, which is an immobilized second molecule capable of specifically binding to the substance to be tested;3) bringing the liquid sample into contact with the detection probe;4) bringing the liquid sample, which has been in contact with the detection probe, into contact with the capture probe; and 5) adding a hydrogen-donor substrate and a peroxide to the capture probe subject to the step 4) so as to perform color development reaction. This invention further provides a nanozyme immunochromatographic detection apparatus for detecting a substance to be tested in a liquid sample.
Liu G.,CAS Institute of Biophysics
Nature Structural and Molecular Biology | Year: 2014
During translation, elongation factor G (EF-G) catalyzes the translocation of tRNA2-mRNA inside the ribosome. Translocation is coupled to a cycle of conformational rearrangements of the ribosomal machinery, and how EF-G initiates translocation remains unresolved. Here we performed systematic mutagenesis of Escherichia coli EF-G and analyzed inhibitory single-site mutants of EF-G that preserved pretranslocation (Pre)-state ribosomes with tRNAs in A/P and P/E sites (Pre-EF-G). Our results suggest that the interactions between the decoding center and the codon-anticodon duplex constitute the barrier for translocation. Catalysis of translocation by EF-G involves the factor's highly conserved loops I and II at the tip of domain IV, which disrupt the hydrogen bonds between the decoding center and the duplex to release the latter, hence inducing subsequent translocation events, namely 30S head swiveling and tRNA2-mRNA movement on the 30S subunit.
Guo B.,CAS Institute of Biophysics
Nature Cell Biology | Year: 2014
The mechanism by which nutrient status regulates the fusion of autophagosomes with endosomes/lysosomes is poorly understood. Here, we report that O-linked β-N-acetylglucosamine (O-GlcNAc) transferase (OGT) mediates O-GlcNAcylation of the SNARE protein SNAP-29 and regulates autophagy in a nutrient-dependent manner. In mammalian cells, OGT knockdown, or mutating the O-GlcNAc sites in SNAP-29, promotes the formation of a SNAP-29-containing SNARE complex, increases fusion between autophagosomes and endosomes/lysosomes, and promotes autophagic flux. In Caenorhabditis elegans, depletion of ogt-1 has a similar effect on autophagy; moreover, expression of an O-GlcNAc-defective SNAP-29 mutant facilitates autophagic degradation of protein aggregates. O-GlcNAcylated SNAP-29 levels are reduced during starvation in mammalian cells and in C. elegans. Our study reveals a mechanism by which O-GlcNAc-modification integrates nutrient status with autophagosome maturation. © 2014 Nature Publishing Group
CAS Institute of Biophysics | Date: 2015-10-28
The present invention discloses novel compositions and methods for enhancing cardiac differentiation efficiency of stem cells or promoting ventricular and atrial cardiomyocytes formation from stem cells. The present invention also discloses the atrial and ventricular cardiomyocytes formed from the stem cells, and the uses of the cardiomyocytes for repairing cardiac injuries and screening for new medicaments for treating cardiac injuries.
CAS Institute of Biophysics | Date: 2014-05-21
The invention relates to a bifunctional tumor diagnostic reagent and a method for tumor diagnosis. The reagent consists of a protein shell specifically recognizing a cancer tissue and/or a cancer cell and an inorganic nano-core having the catalytic activity of a peroxidase. The bifunctional tumor diagnostic reagent has two functions, i.e., tumor specific identification and color development, and enables the tumor specific identification and the color development to be completed in one step, and the operation of the process is simple and convenient.
CAS Institute of Biophysics | Date: 2015-07-08
Provided in the present invention is a method for inducing pluripotent stem cells to differentiate into ventricular myo-cytes in vitro, which is achieved by maintaining, amplifying and culturing pluripotent stem cells in vitro, adding a substance capable of activating the Smadl/5/8 signaling pathway directly or indirectly into the culture medium when pluripotent stem cells are in the middle stage of myocardial differentiation, i.e. the period of differentiating into cardiac muscle cells from mesoderm cells or myocardial precursor cells, which enables stem cells to differentiate into ventricular myocytes directionally. Ventricular myocytes with biological activity and function are obtained successfully by means of the method of the present invention, which reveals the regulatory mechanism during differentiation of myocardial precursor cells into ventricular myocytes; moreover, the human ventricular myo-cytes obtained via differentiation can be widely used in treating myocardial infarction by cell transplantation, in toxicological analys - is of the heart and in the development of heart-related drugs.